• China’s NMPA cleared Akeso’s ivonescimab with chemotherapy for first-line advanced squamous NSCLC, expanding a key partnered program for Summit Therapeutics.
• Authorization follows Phase III HARMONi-6, which reported statistically significant overall survival superiority versus tislelizumab with chemotherapy.
• Ivonescimab remains unapproved in Summit’s licensed markets; its U.S. BLA for a separate NSCLC setting has a Nov. 14, 2026 PDUFA date.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Summit Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608120922BIZWIRE_USPR_____20260812_BW443578) on August 12, 2026, and is solely responsible for the information contained therein.